CD200 and lymphoma: For NOD/SCID mice injected with human lymphoma cells expressing CD200 and treated with an anti-CD200 antibody without effector functions, i.e. a ‘pure’ blocking antibody, there was superior tumour growth inhibition versus an antibody with effector functions [47].